Decks have been cleared for Bengaluru-based Syngene International to begin a phase II clinical trial to test tablet based Covid-19 vaccine in India. Central Drugs Laboratory (CDL), Kasauli, has cleared batches of the tablet vaccine which Syngene has imported from American biotechnology company, Vaxart.
“Samples samples of -VXA-CoV2 Enteric-coated tablets manufactured by Vaxart have been cleared by the laboratory at CDL Kasauli,” said a person in the know. The trial aims at understanding the safety, efficacy and immunogenicity of an adenoviral-vector based tablet vaccine against Covid-19.
Vaxart had started trials of its oral recombinant tablet vaccine in October last year. It enrolled 96 participants at four centres in the US. Participants included both-the untreated as well as previously vaccinated subjects. The company had planned to commence a global, placebo-controlled efficacy trial recruiting more subjects. Vaxart is going to present the initial findings of the trials of oral tablet vaccine administration at the World Vaccine Congress Europe 2022 in Barcelona, Spain this Thursday.
Source: Economic Times